ProQR Appoints Peter A. Beal, PhD, as Chief ADAR Scientist Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 10, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV. December 10, 2024
ProQR Prices $90 Million Underwritten Public Offering of Ordinary Shares Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., March 30, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. March 31, 2021
ProQR Prices $90.6 Million Underwritten Public Offering of Ordinary Shares Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 07, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. September 07, 2018
ProQR Announces R&D Day and Provides Update on Innovation Portfolio Press release First Investor R&D Day on March 14, 2016 in New York, NY November 30, 2015
ProQR Prices $50 Million Underwritten Public Offering of Ordinary Shares Press release LEIDEN, The Netherlands and CAMBRIDGE, Mass., Oct. 15, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. October 16, 2019
ProQR Appoints Naveed Shams, MD, PhD as Chief Scientific Officer Press release Proven leader with deep worldwide ophthalmology experience, including multiple approvals globally October 05, 2020
ProQR to Present at Scientific and Investor Conferences in September Press release LEIDEN, the Netherlands, Sept. 06, 2016 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. September 06, 2016
ProQR to Present at Upcoming JMP Securities Life Sciences Conference Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. June 10, 2021
ProQR Announces Conference Call to Discuss Axiomer® RNA Editing Platform Press release LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 22, 2022 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. December 22, 2022
